Ascentage Pharma Group International (NASDAQ:AAPG) Shares Gap Down – Time to Sell?

Shares of Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) gapped down before the market opened on Tuesday . The stock had previously closed at $28.38, but opened at $27.31. Ascentage Pharma Group International shares last traded at $27.31, with a volume of 633 shares.

Analysts Set New Price Targets

A number of analysts recently commented on AAPG shares. Truist Financial set a $51.00 target price on shares of Ascentage Pharma Group International in a research note on Monday, November 24th. BTIG Research began coverage on shares of Ascentage Pharma Group International in a research note on Monday, November 10th. They set a “buy” rating and a $50.00 price objective for the company. Piper Sandler started coverage on shares of Ascentage Pharma Group International in a report on Wednesday, November 5th. They set an “overweight” rating and a $48.00 price objective on the stock. Rodman & Renshaw began coverage on Ascentage Pharma Group International in a research report on Tuesday. They set a “buy” rating and a $48.00 price target for the company. Finally, Lucid Cap Mkts upgraded Ascentage Pharma Group International to a “strong-buy” rating in a research note on Monday, December 15th. One investment analyst has rated the stock with a Strong Buy rating and six have issued a Buy rating to the stock. According to data from MarketBeat.com, Ascentage Pharma Group International has a consensus rating of “Buy” and an average price target of $48.40.

Ascentage Pharma Group International Stock Down 3.6%

The firm’s 50 day moving average is $29.78 and its 200-day moving average is $35.89. The company has a quick ratio of 1.53, a current ratio of 1.54 and a debt-to-equity ratio of 1.31.

Institutional Investors Weigh In On Ascentage Pharma Group International

A number of institutional investors have recently modified their holdings of AAPG. UBS Group AG increased its stake in shares of Ascentage Pharma Group International by 149.4% in the 3rd quarter. UBS Group AG now owns 18,345 shares of the company’s stock valued at $716,000 after purchasing an additional 10,988 shares in the last quarter. XY Capital Ltd increased its position in shares of Ascentage Pharma Group International by 224.2% in the third quarter. XY Capital Ltd now owns 18,120 shares of the company’s stock valued at $707,000 after buying an additional 12,530 shares in the last quarter. Tema Etfs LLC acquired a new stake in Ascentage Pharma Group International in the 2nd quarter valued at $610,000. Hsbc Holdings PLC purchased a new stake in Ascentage Pharma Group International in the 2nd quarter worth $391,000. Finally, Citadel Advisors LLC purchased a new stake in Ascentage Pharma Group International in the 3rd quarter worth $383,000.

About Ascentage Pharma Group International

Ascentage Pharma Group International is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapeutics that modulate programmed cell death pathways, including the Bcl‐2 family and the MDM2–p53 axis. Its pipeline features orally bioavailable inhibitors such as APG-2575, a selective Bcl-2 inhibitor, and APG-115, a potent MDM2 antagonist, both aimed at reactivating apoptosis in cancer cells across hematologic malignancies and solid tumors.

Founded in 2008 by biotechnology entrepreneur Dr.